Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | BCL9 | O00512 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL763026 | 0.91 | HTR2A (0.64) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL27355874 | 0.90 | HTR2A (0.60) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL21097206 | 0.88 | HTR2A (0.61) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL7411825 | 0.88 | HTR2A (0.61) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL12355356 | 0.88 | HTR2A (0.61) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL7412947 | 0.88 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL15760497 | 0.86 | HTR2A (0.58) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL18458538 | 0.86 | HTR2A (0.58) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL6600772 | 0.85 | HTR2A (0.61) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL31639396 | 0.85 | HTR2A (0.57) | HTR2ABCL9CTNNB1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011875-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3710438-B1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8536343-B2 | Arylamidine derivative, salt thereof and antifungal agent containing those | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2571862-A1 | PRODRUG OF TRIAZOLONE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-8173157-B2 | Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-1967190-B1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO LTD (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20100098750-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100098750-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100098750-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2070536-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT | Toyama Chemical Co., Ltd. (JP) | 2009-06-17 | — | — | EP | disclosed |
| EP-1967190-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-09-10 | — | — | EP | disclosed |
| WO-2004002985-A1 | PEPTIDIC THROMBIN INHIBITOR COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098750-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYLAMIDINE DERIVATIVE AND METHOD OF USING THE PHARMACEUTICAL COMPOSITION IN COMBINATION WITH ANTIFUNGAL AGENT | PFN1, ACR, PDXK | HTR2A 4372/4885BCL9 4498/4885CTNNB1 4818/4885 |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | F7, TFPI, TFPI2 | HTR2A 3114/4885BCL9 2680/4885CTNNB1 3862/4885 |
| US-20100016602-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF AND ANTIFUNGAL AGENT CONTAINING THOSE | ERG28, DPM1, NAT1 | HTR2A 4237/4885BCL9 2659/4885CTNNB1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.